Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xbrane Biopharma ABSTU:7XB0 -2.85%51 Days Inventory is 388.86 as of Jun. 2026, which is 176% above its 10-year median of 140.96. GuruFocus rates STU:7XB0 with a GF Score™ of 51/100 and a GF Value™ of €0.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 640 Biotechnology companies, Xbrane Biopharma AB ranks worse than 90.47% on this metric.
The historical rank and industry rank for Xbrane Biopharma AB's Days Inventory or its related term are showing as below:
STU:7XB0'
s Days Inventory Range Over the Past 10 Years
Min: 64.13 Med: 140.96 Max: 223718.29
Current: 929.71
During the past 13 years, Xbrane Biopharma AB's highest Days Inventory was 223718.29. The lowest was 64.13. And the median was 140.96.
STU:7XB0's Days Inventory is ranked worse than 90.47% of 640
companies
in the Biotechnology industry
Industry Median: 183.115
vs STU:7XB0: 929.71
Xbrane Biopharma AB's Days Inventory
increased
from Jun. 2025 (0.00) to Jun. 2026 (388.86).
It might indicate that Xbrane Biopharma AB's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Xbrane Biopharma AB's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.23.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xbrane Biopharma AB's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 4.04.
Xbrane Biopharma AB (STU:7XB0) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Xbrane Biopharma AB's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Xbrane Biopharma AB's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Xbrane Biopharma AB Days Inventory Related Terms
Xbrane Biopharma AB Days Inventory Historical Data
* Premium members only.
The historical data trend for Xbrane Biopharma AB's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7XB0 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Xbrane Biopharma AB's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xbrane Biopharma AB Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Days Inventory distribution charts can be found below:
* The bar in red indicates where Xbrane Biopharma AB's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xbrane Biopharma AB (STU:7XB0) has a Days Inventory of 388.86 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xbrane Biopharma AB and its competitors. This is 176% above median its historical median of 140.96. Over the past decade, Xbrane Biopharma AB's Days Inventory has ranged from 64.13 to 223,718.29. According to the industry distribution chart, Xbrane Biopharma AB ranks #579 out of 640 companies in the Biotechnology industry, placing it in the top 90.5%.
Is Xbrane Biopharma AB's Days Inventory too high?
Xbrane Biopharma AB's current Days Inventory of 388.86 is 176% above median its 10-year median of 140.96. Over the past 10 years, this metric has ranged from a low of 64.13 to a high of 223,718.29. The Biotechnology industry median Days Inventory is 183.12. Xbrane Biopharma AB's value of 388.86 is 112.4% above this industry median. Based on the distribution chart, Xbrane Biopharma AB ranks #579 out of 640 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xbrane Biopharma AB has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xbrane Biopharma AB ranks #579 out of 640 companies for Days Inventory. This places Xbrane Biopharma AB in the lower half of its industry. The industry median Days Inventory is 183.12. Xbrane Biopharma AB's value of 388.86 is 112.4% above this benchmark. Historically, Xbrane Biopharma AB's own Days Inventory has ranged from 64.13 to 223,718.29 over the past decade. While the company's 10-year median is 140.96 vs. the industry median of 183.12, Xbrane Biopharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.12, based on 640 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xbrane Biopharma AB's current Days Inventory of 388.86 is 112.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Xbrane Biopharma AB and its competitors. For the Biotechnology industry, the median Days Inventory is 183.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xbrane Biopharma AB's current Days Inventory is 388.86, which is 176% above median its own 10-year median of 140.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (STU:7XB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.51, compared to a current price of €0.75 — trading 47.1% above its estimated fair value. The current Days Inventory is 388.86, which is 176% above median its 10-year median of 140.96 and 112.4% above the Biotechnology industry median of 183.12. Xbrane Biopharma AB's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Xbrane Biopharma AB (STU:7XB0), the current Days Inventory is 388.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xbrane Biopharma AB (STU:7XB0) Overvalued in 2026?
Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued.
The current stock price of €0.75 is trading 47.1% above its estimated GF Value™ of €0.51.
GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.
Key valuation signals for STU:7XB0:
Days Inventory: 388.86 (176% above median its 10-year median of 140.96)
GF Value™: €0.51 vs. price of €0.75 (47.1% above fair value)
Industry Position: 112.4% above the Biotechnology median (#579 of 640)
No single metric tells the full story. See the STU:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
51GF Score
Get the complete analysis for STU:7XB0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7XB0 has been successfully added to your 
